Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

$(2,911) $(1,102) $(4,013)

Basic and diluted

net loss per

share $(0.31) $(0.04) $(0.35) $(0.19) $(0.07) $(0.26)

Research and

development

expenses $8,870 $367 $9,237 $9,975 $549 $10,524

General and

administrative

expenses $1,768 $495 $2,263 $1,573 $553 $2,126

Six Months Ended Six Months Ended

June 30, 2008 (1) June 30, 2007 (1)

Stock- Stock-

based Reported based Reported

compensation GAAP compensation GAAP

non-GAAP expense results non-GAAP expense results

Net loss $(1,992) $(1,488) $(3,480) $(3,020) $(2,091) $(5,111)

Basic and diluted

net loss per

share $(0.10) $(0.07) $(0.17) $(0.20) $(0.14) $(0.33)

Research and

development

expenses $19,925 $661 $20,586 $19,492 $1,050 $20,542

General and

administrative

expenses $3,557 $827 $4,384 $3,318 $1,041 $4,359

SGX PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

June 30, December 31,

2008 2007

Assets

Cash, cash equivalents and short-term investments $23,676 $38,990

Accounts receivable 954 2,706

Other current assets 1,217 1,187

Property and equipment, net 3,5
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... Life Sciences Holdings, Inc. (OTC Bulletin Board: ... discovery, development and commercialization of novel drugs in the ... announced that it will present at the Biotech Showcase ... Francisco. (Logo: http://photos.prnewswire.com/prnh/20080218/ALSLOGO ) ...
... Jan. 4, 2011 Vaccinex, Inc. announced today that ... a Phase 1 clinical trial to assess the safety, ... in cancer patients with advanced solid tumors. ... novel humanized antibody that blocks the activity of semaphorin ...
... S.C., Jan. 4, 2011 Zeus, Inc., a global ... it has expanded its capabilities and is now able ... new 5,000-sq-ft Class 7 manufacturing environment. This expansion allows ... more controlled environment, resulting in compliance with stricter regulatory ...
Cached Biology Technology:Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference 2Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors 2Zeus Expands Class 7 Capabilities to Include the Processing of Advanced Polymers 2
(Date:10/15/2014)... is a non-traditional biophysics textbook and it describes how ... journey of discovery into biological systems and provides an ... It is about how our genes make proteins that ... of cells in an organism. It quantifies the principles ... can be found on both large and small scales. ...
(Date:10/15/2014)... Alt will be awarded the 44th Rosenstiel Award for ... his pioneering research exploring the mechanisms of genomic instability ... cells. Alt is the second alumnus to win the ... Prize in 2003. , Alt is the Charles A. ... Harvard Medical School and an investigator at the Howard ...
(Date:10/14/2014)... N.Y. – Scientists have sequenced the house fly genome ... one might expect from an insect that thrives in ... published Oct. 14 in the journal Genome Biology ... biology and of how flies quickly adapt to resist ... Adult house flies (Musca domestica) carry and transmit more ...
Breaking Biology News(10 mins):New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2House fly genome reveals expanded immune system 2
... in at least one of four key subjects English, ... more of three specific dopamine gene variations, according to a ... The Florida State University. The research sheds new ... and high school, and on the interplay of specific genes ...
... for protons: just like the electronic component determines the ... ensures that protons can only pass through a cell ... role here as active components of the diode. The ... Biophysics at the RUB) were able to observe this ...
... psoriasis and psoriatic arthritis are one step closer to ... Psoriasis Victor Henschel BioBank DNA samples for use in ... that hopes to uncover the unknowns about the genetics ... disfiguring disease of the immune system that appears on ...
Cached Biology News:Low grades in adolescence linked to dopamine genes 2Bochum's researchers discover proton diode 2U-M researchers receive largest single collection of psoriasis DNA samples 2
... We deliversoluble protein or No Charge to ... best soluble protein results , 24 solubility ... , Powerful results on your most insoluble ... Service (SOS) uses proprietary tools and know-how ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
... Rapid-Screen cDNA Library Panels were designed for ... sets of PCRs to identify the desired ... performed in a 96-well "Master Plate," where ... clones. Having identified the positive well(s) by ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
Biology Products: